Skip to main content
17/11/2021

Vall d’Hebron includes the first patient in a clinical trial for Oryzon to treat schizophrenia

Hospital Vall d'Hebron

17/11/2021

The EVOLUTION trial is currently in phase IIb and it will evaluate the effect of the Vafidemstat drug on cognitive effects and the negative effects deriving from the illness.

Vall d’Hebron includes the first patient as part of phase IIb of the EVOLUTION project, by the company Oryzon Genomics. The research studies the effects of the drug Vafidemstat on patients suffering from schizophrenia in order to improve their quality of life.  

EVOLUTION (EudraCT No.: 2021-000350-26) is a double-blind, placebo-controlled, multicentric randomised phase IIb trial lasting 24 weeks, to evaluate the effectiveness and safety of the drug Vafidemstat on adult patients suffering from schizophrenia who are undergoing stable antipsychotic therapy. The main objectives of the trial are to evaluate the effect of Vafidemstat on the negative symptoms of schizophrenia and to evaluate the improvement in the cognitive deterioration associated with the illness. The treatment and monitoring will be carried out over six months. In addition to Vall d’Hebron, there are other Spanish centres participating in the study and it is expected that it will involve around 100 patients.

Dr Michael Ropacki, medical director of SNC at Oryzon stated: “We are excited about the inclusion of the first patients in the EVOLUTION study. Taking into account the important profile of the side effects of atypical antipsychotics used to treat schizophrenia, vafidemstat has enormous potential to be a treatment option that is safe, efficient and able to better tolerate the cognitive dysfunction and negative symptoms of the illness”.

 

About Vafidemstat

Vafidemstat (ORY-2001) is an orally administered LSD1 inhibitor optimised for active SNC administered orally. The molecule acts on different levels, reducing cognitive deterioration, memory loss and neural inflammation, and also has a neuroprotector effect.

Related news

El Dr. Gabriel Sampol, del Servei de Pneumologia i grup de Pneumologia del VHIR, el Dr. Jordi Giralt, cap del Servei d'Oncologia Radioteràpica i cap del grup d’Oncologia Radioteràpica del VHIO, el Dr. Josep Antoni Ramos Quiroga, cap del Servei de Psiquiatria i cap del grup de Psiquiatria, Salut Mental i Addiccions del VHIR, i el Dr. Víctor M. Vargas, del Servei d'Hepatologia, guardonats pel COMB.

Enguany la Jornada ha estat dedicada a la recerca a l’abordatge de la nova realitat en salut mental postpandèmia.

Els estudis se centraran en els trastorns del neurodesenvolupament, la prevenció del suïcidi, el trastorn bipolar i la depressió.

Related professionals

José Antonio Ramos Quiroga

José Antonio Ramos Quiroga

Head of group
Psychiatry, Mental Health and Addictions
Read more
Francisco Collazos Sanchez

Francisco Collazos Sanchez

Predoctoral researcher
Psychiatry, Mental Health and Addictions
Read more
Gemma Nieva Rifa

Gemma Nieva Rifa

Research technician
Psychiatry, Mental Health and Addictions
Read more
Vanesa Richarte Fernández

Vanesa Richarte Fernández

Senior researcher
Psychiatry, Mental Health and Addictions
Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.